Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination

This multicenter screening study will be conducted in order to determine a subject's tumor
antigen expression profile and HLA subtype, and subsequent eligibility for Adaptimmune
sponsored clinical treatment trials studying the safety and efficacy of autologous
genetically modified T-cells engineered with enhanced TCRs targeting specific antigens. No
treatment intervention will occur as part of this screening study. Specific Adaptimmune
sponsored interventional protocols have been designated to utilize this screening protocol to
determine preliminary eligibility. Therefore, details of the available interventional
clinical trial(s) (e.g., HLA subtype, tumor antigen, and other eligibility criteria) should
be understood before consenting subjects for this screening protocol.

For this screening study, subjects with confirmed advanced solid or hematologic malignancy or
recurrent disease, as described in the respective Adaptimmune clinical trial protocol(s),
will be required to provide a blood sample for diagnostic analysis. The blood sample will be
used for HLA subtype analysis. If the results of the analysis match the HLA subtype specified
in the available interventional clinical trial(s), then the subject will be required to
provide either an archival tumor specimen or fresh tumor tissue biopsy. The tumor specimen
will be screened at a central laboratory for the expression (gene or protein) of multiple
antigens using Clinical Trial Assays. The Clinical Trial Assays to be used in this protocol
have undergone CLIA validation to establish the sensitivity, specificity and performance of
the assays. The antigens to be screened may include, but are not limited to the following:
NY-ESO-1 and/or LAGE-1a and MAGE-A10. Based upon both the tumor antigen expression and the
HLA subtype, if eligible, subjects will be referred to appropriate available interventional
trial(s) at the discretion of the Investigator.

The secondary objective of the study is the collection and analysis of tumor tissue specimens
to enable the development and validation of single and/or multiple-marker ('multiplex') IVD
assay(s) for antigen expression profiling. It is a regulatory requirement to develop the
IVD(s) as a companion diagnostic(s) to accompany a future new indication drug application(s).
Therefore all tumor specimens from this study will be retained by Adaptimmune for companion
diagnostic validation purposes.

Inclusion Criteria

1. Signed written informed consent;

2. Histologically or cytologically confirmed diagnosis of advanced solid or hematologic
malignancy or recurrent disease, as described in the respective Adaptimmune clinical
treatment protocol (including, but not limited to myeloma, melanoma, NSCLC, head and
neck, gastric and bladder cancer);

3. Male or female ≥ 18 years of age;

4. Life expectancy > 3 months;

5. Ability to provide a blood sample;

6. Ability to provide one of the following tumor tissue samples:

i. formalin-fixed, paraffin-embedded (FFPE) tumor block or tissue sections from a
current lesion/the most current setting, or a fresh biopsy is feasible, OR;

ii. a FFPE archival primary tumor block or tissue sections

Exclusion Criteria:

1. Any bleeding diathesis or coagulopathy, which at the discretion of the Investigator
may put the subject at risk.

2. Any serious and/or unstable pre-existing medical, psychiatric disorder or other
conditions that could interfere with subject's safety, obtaining informed consent or
compliance to the screening study procedures.